Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise is Breyanzi, whose sales amounted to $263 million in the fourth quarter of 2024, an increase of 160.4% year-on-year. On the other hand, Camzyos is gradually becoming the flagship of Bristol-Myers Squibb's cardiovascular franchise.
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a recent share price decline, BMY's strategic cost reductions, debt repayments, and dividend commitments highlight its long-term growth and shareholder return focus. LOE risks for key drugs like Yervoy and Eliquis and cautious 2025 guidance suggest temporary volatility, justifying a "Hold" rating at the current share price.
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focuses on developing a 'growth portfolio' and pipeline execution, with promising approvals like subcutaneous Opdivo and Cobenfy. Despite significant debt and uncertainty, Bristol-Myers is a compelling contrarian buy if pipeline execution offsets the $25B at-risk revenue from patent expirations.
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so quickly.
Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Chris Shibutani - Goldman Sachs Tim Anderson - Bank of America Mohit Bansal - Wells Fargo Securities Evan Seigerman - BMO Capital Markets Akash Tewari - Jefferies Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities David Risinger - Leerink Partners Matt Phipps - William Blair Steve Scala - Cowen Kripa Devarakonda - Truist Securities Olivia Brayer - Cantor Fitzgerald James Shin - Deutsche Bank Sean McCutchen - Raymond James Alexandria Hammond - Wolfe Research Operator Welcome to the Bristol-Myers Squibb Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 Earnings
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.
